|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance via activating TFEB-mediated autophagy——lysosomal pathway显示文摘Nonalcoholic fatty liver disease(NAFLD) is characterized by hepatic steatosis and insulin resistance and there are currently no approved drugs for its treatment.Hyperactivation of mTOR complex1(mTORCl) and subsequent impairment of the transcription factor EB(TFEB)-mediated autophagy-lysosomal pathway(ALP) are implicated in the development of NAFLD.Accordingly,agents that augment hepatic TFEB transcriptional activity may have therapeutic potential against NAFLD.The objective of this study was to investigate the effects of nuciferine,a major active component from lotus leaf,on NAFLD and its underlying mechanism of action.Here we show that nuciferine activated ALP and alleviated steatosis,insulin resistance in the livers of NAFLD mice and palmitic acid-challenged hepatocytes in a TFEB-dependent manner.Mechanistic investigation revealed that nuciferine interacts with the Ragulator subunit hepatitis B X-interacting protein and impairs the interaction of the Ragulator complex with Rag GTPases,thereby suppressing lysosomal localization and activity of mTORC1,which activates TFEB-mediated ALP and further ameliorates hepatic steatosis and insulin resistance.Our present results indicate that nuciferine may be a potential agent for treating NAFLD and that regulation of the mTORCl-TFEB-ALP axis could represent a novel pharmacological strategy to combat NAFLD. | Xiliang Du Chiara Di Malta Zhiyuan Fang Taiyu Shen Xiaodi Niu Meng Chen Bo Jin Hao Yu Lin Lei Wenwen Gao Yuxiang Song Zhe Wang Chuang Xu Zhijun Cao Guowen Liu Xinwei Li | 2022 | Acta Pharmaceutica Sinica B2022，12，6： | 2 |
| 2 | Towards carbon neutrality:A study on China's long-term low-carbon transition pathways and strategies显示文摘As the world's biggest carbon dioxide(CO_(2))emitter and the largest developing country,China faces daunting challenges to peak its emissions before 2030 and achieve carbon neutrality within 40 years.This study fully considered the carbon-neutrality goal and the temperature rise constraints required by the Paris Agreement,by developing six long-term development scenarios,and conducting a quantitative evaluation on the carbon emissions pathways,energy transformation,technology,policy and investment demand for each scenario.This study combined both bottom-up and top-down methodologies,including simulations and analyses of energy consumption of end-use and power sectors(bottom-up),as well as scenario analysis,investment demand and technology evaluation at the macro level(top-down).This study demonstrates that achieving carbon neutrality before 2060 translates to significant efforts and overwhelming challenges for China.To comply with the target,a high rate of an average annual reduction of CO_(2) emissions by 9.3%from 2030 to 2050 is a necessity,which requires a huge investment demand.For example,in the 1.5℃ scenario,an investment in energy infrastructure alone equivalent to 2.6%of that year's GDP will be necessary.The technological pathway towards carbon neutrality will rely highly on both conventional emission reduction technologies and breakthrough technologies.China needs to balance a long-term development strategy of lower greenhouse gas emissions that meets both the Paris Agreement and the long-term goals for domestic economic and social development,with a phased implementation for both its five-year and long-term plans. | Jiankun He Zheng Li Xiliang Zhang Hailin Wang Wenjuan Dong Ershun Du Shiyan Chang Xunmin Ou Siyue Guo Zhiyu Tian Alun Gu Fei Teng Bin Hu Xiu Yang Siyuan Chen Mingtao Yao Zhiyi Yuan Li Zhou Xiaofan Zhao Ying Li Danwei Zhang | 2022 | Environmental Science and Ecotechnology2022，，1： | 2 |
| 3 | A glucose biosen- sor based on chitosan glucose oxidase-gold nanoparticles bio composite formed by one-step electrodeposition显示文摘 | Luo Xiliang Xu Jingjuan Du Ying | 2004 | Anal Biochem2004，334，2： | 1 |
| 4 | The E3 ubiquitin ligase NEDD4-1 protects against acetaminophen-induced liver injury by targeting VDAC1 for degradation显示文摘Acetaminophen(APAP)overdose is a major cause of liver injury.Neural precursor cell expressed developmentally downregulated 4—1(NEDD4-1)is an E3 ubiquitin ligase that has been implicated in the pathogenesis of numerous liver diseases;however,its role in APAP-induced liver injury(AILI)is unclear.Thus,this study aimed to investigate the role of NEDD4-1 in the pathogenesis of AILI.We found that NEDD4-1 was dramatically downregulated in response to APAP treatment in mouse livers and isolated mouse hepatocytes.Hepatocyte-specific NEDD4-1 knockout exacerbated APAP-induced mitochondrial damage and the resultant hepatocyte necrosis and liver injury,while hepatocyte-specific NEDD4-1 overexpression mitigated these pathological events both in vivo and in vitro.Additionally,hepatocyte NEDD4-1 deficiency led to marked accumulation of voltage-dependent anion channel 1(VDAC1)and increased VDAC1 oligomerization.Furthermore,VDAC1 knockdown alleviated AILI and weakened the exacerbation of AILI caused by hepatocyte NEDD4-1 deficiency.Mechanistically,NEDD4-1 was found to interact with the PPTY motif of VDAC1 through its WW domain and regulate K48-linked ubiquitination and degradation of VDAC1.Our present study indicates that NEDD4-1 is a suppressor of AILI and functions by regulating the degradation of VDAC1. | Yiwei Zhu Lin Lei Xinghui Wang Linfang Chen Wei Li Jinxia Li Chenchen Zhao Xiliang Du Yuxiang Song Wenwen Gao Guowen Liu Xinwei Li | 2023 | Acta Pharmaceutica Sinica B2023，13，4： | 1 |
| 5 | 显示文摘 | Du Ying Luo Xiliang Xu Jingjuan | 2007 | Bioelectrochemistry2007，70，： | 1 |
| 6 | A simple method to fabricate a chitosan - gold nanoparticles film and its application in glucose biosensor显示文摘 | DU Ying LUO Xiliang XU Jingjuan | 2007 | Bioelectrochemistry2007，70，2： | 1 |
| 7 | A glucose biosensor based on chitosan-gtucose oxidase-gold nanoparticles bio- composite formed by one-step electrodeposition 显示文摘 | Xiliang Luo Jingjuan Xu Ying Du | 2004 | Ana- lytical Biochemistry2004，334，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员